PIK3CA and neoplasm: Broader genetic profiling by NGS of baseline ctDNA samples revealed co-occurring alterations in PIK3CA in 9/28 (32%) patients with sufficient tumor DNA for analysis (Fig. 2), a slightly greater rate than that (19–20%) reported by The Cancer Genome Atlas and METABRIC analyses18–20.